MYC and Burkitt lymphoma: The administration of synthetic miR-28a-5p mimicked using a liposome delivery approach, impaired proliferation and survival of lymphoma cells, and abrogated tumor growth in MD901 DLBCL and Ramos human BL xenograft mouse models and in a λ-MYC transgenic mouse BL model [39].